English

ImmunoGen, Inc.

EDGAR

IMGN Quarterly report (10-Q) · filed 2023-11-02

202 filing records in this dataset, filed from 1995-05-15 to 2023-11-02. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

9.29 million Unit12

2018 Q4 · Unit12

Exact inputs and evidence

Revenue: 9287000 Unit12 Source

Cash and cash equivalents: 606 million Unit_Standard_USD_BvOHEeZT8kCMjyqcQLdbbQ 2023-09-30 Source
Exact value

605500000 Unit_Standard_USD_BvOHEeZT8kCMjyqcQLdbbQ
Long-term debt including current maturities: Not available
Shares outstanding: 266 million Unit_Standard_shares_X6gESLqOYUa4-DijZK7RsA 2023-09-30 Source
Exact value

265842000 Unit_Standard_shares_X6gESLqOYUa4-DijZK7RsA

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2023-11-02.

Financial data available through: 2022-12-31.

Coverage by financial measure

Revenue: 6 of 11 periods available· newest 2017-12-31
Operating income: 3 of 11 periods available· newest 2022-12-31
Net income: 3 of 11 periods available· newest 2022-12-31
Operating cash flow: 3 of 11 periods available· newest 2022-12-31
Capital expenditure: 3 of 11 periods available· newest 2022-12-31
Total assets: Multiple units; comparison withheld· newest 2022-12-31
Total liabilities: Multiple units; comparison withheld· newest 2022-12-31
Current assets: Multiple units; comparison withheld· newest 2022-12-31
Current liabilities: Multiple units; comparison withheld· newest 2022-12-31
Cash and cash equivalents: Multiple units; comparison withheld· newest 2022-12-31
long term debt: No compatible figures in this window
Shares outstanding: Multiple units; comparison withheld· newest 2022-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
−Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 83.63 million

Prior period

−Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 139.3 million

2021-01-01 – 2021-12-31
Current period

−Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 222.93 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-222929000 − -139303000 = -83626000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA

-139303000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-222929000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · ImmunoGen, Inc. · 2022-12-31 ImmunoGen, Inc. (edgar:855654) Year-over-year change in Net income: -83626000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:05:41Z Snapshot: c9f8017d027214c342568b313855522615578f98fd10500a38e3fc0a88244ab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/855654?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -222929000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/855654/000155837023002558/imgn-20221231x10k.htm#1237952 Filing: 000155837023002558 Input fundies:NetIncome: -139303000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/855654/000155837023002558/imgn-20221231x10k.htm#1190932 Filing: 000155837023002558
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
−Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 60.39 million

Prior period

−Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 169.42 million

2021-01-01 – 2021-12-31
Current period

−Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 229.8 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

-229802000 − -169416000 = -60386000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA

-169416000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
-229802000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · ImmunoGen, Inc. · 2022-12-31 ImmunoGen, Inc. (edgar:855654) Year-over-year change in Operating cash flow: -60386000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:05:41Z Snapshot: c9f8017d027214c342568b313855522615578f98fd10500a38e3fc0a88244ab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/855654?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -229802000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/855654/000155837023002558/imgn-20221231x10k.htm#1356810 Filing: 000155837023002558 Input fundies:OperatingCashFlow: -169416000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/855654/000155837023002558/imgn-20221231x10k.htm#1357822 Filing: 000155837023002558
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-4.9%

Prior period

Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 1.43 million

2021-01-01 – 2021-12-31
Current period

Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 1.36 million

2022-01-01 – 2022-12-31

Exact inputs and evidence

1364000 − 1434000 = -70000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA

1434000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA · 2021-01-01 – 2021-12-31
Inspect prior input Prior source
1364000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA · 2022-01-01 – 2022-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · ImmunoGen, Inc. · 2022-12-31 ImmunoGen, Inc. (edgar:855654) Year-over-year change in Capital expenditure: -70000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:05:41Z Snapshot: c9f8017d027214c342568b313855522615578f98fd10500a38e3fc0a88244ab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/855654?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1364000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/855654/000155837023002558/imgn-20221231x10k.htm#1365766 Filing: 000155837023002558 Input fundies:CapitalExpenditure: 1434000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/855654/000155837023002558/imgn-20221231x10k.htm#1366824 Filing: 000155837023002558
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2018 2017-01-01 – 2017-12-31

Revenue Unit12 115.45 million 100% of revenue
Operating costs Derived Unavailable An input is unavailable.
Operating income Unavailable An input is unavailable.
Tax, interest and other Derived Unavailable An input is unavailable.
Net income Unavailable An input is unavailable.

Cash

Operating cash flow Unavailable An input is unavailable.
Capital expenditure Unavailable An input is unavailable.
Free cash flow Derived Unavailable An input is unavailable.

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2013 Not shown: operating income or net income is not reported.
2014 Not shown: operating income or net income is not reported.
2015 Not shown: operating income or net income is not reported.
2016 Not shown: operating income or net income is not reported.
2017 Not shown: operating income or net income is not reported.
2018 Not shown: operating income or net income is not reported.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2013 2012-07-01 – 2013-06-30	35535000	Unavailable	Unavailable	Unavailable	Unavailable	Unavailable	Source 2012-07-01 – 2013-06-30: 35535000 Unit12 Inspect Revenue Open source
2014 2013-07-01 – 2014-06-30	59896000	Unavailable	Unavailable	Unavailable	Unavailable	Unavailable	Source 2013-07-01 – 2014-06-30: 59896000 Unit12 Inspect Revenue Open source
2015 2014-07-01 – 2015-06-30	85541000	Unavailable	Unavailable	Unavailable	Unavailable	Unavailable	Source 2014-07-01 – 2015-06-30: 85541000 Unit12 Inspect Revenue Open source
2016 2015-07-01 – 2016-06-30	60002000	Unavailable	Unavailable	Unavailable	Unavailable	Unavailable	Source 2015-07-01 – 2016-06-30: 60002000 Unit12 Inspect Revenue Open source
2017 2016-01-01 – 2016-12-31	48628000	Unavailable	Unavailable	Unavailable	Unavailable	Unavailable	Source 2016-01-01 – 2016-12-31: 48628000 Unit12 Inspect Revenue Open source
2018 2017-01-01 – 2017-12-31	115447000	Unavailable	Unavailable	Unavailable	Unavailable	Unavailable	Source 2017-01-01 – 2017-12-31: 115447000 Unit12 Inspect Revenue Open source

Amounts are exact, in Unit12.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

Unit12 115.4M 2018

Values and sources

Revenue values and source evidence
Period	Series	Value(Unit12)	Source evidence
20132013-06-30	Revenue	35535000	Revenue: 35535000 Open source
20142014-06-30	Revenue	59896000	Revenue: 59896000 Open source
20152015-06-30	Revenue	85541000	Revenue: 85541000 Open source
20162016-06-30	Revenue	60002000	Revenue: 60002000 Open source
20172016-12-31	Revenue	48628000	Revenue: 48628000 Open source
20182017-12-31	Revenue	115447000	Revenue: 115447000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

137.4% 2018

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20132013-06-30	Year over year	No prior comparable period	Revenue: 35535000 Open source
20142014-06-30	Year over year	68.6%	Revenue: 59896000 Open source Revenue: 35535000 Open source
20152015-06-30	Year over year	42.8%	Revenue: 85541000 Open source Revenue: 59896000 Open source
20162016-06-30	Year over year	-29.9%	Revenue: 60002000 Open source Revenue: 85541000 Open source
20172016-12-31	Year over year	No prior comparable period	Revenue: 48628000 Open source
20182017-12-31	Year over year	137.4%	Revenue: 115447000 Open source Revenue: 48628000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Not enough comparable data to show this history.

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
2013-06-30	Operating margin	Not reported	Revenue: 35535000 Open source
2014-06-30	Operating margin	Not reported	Revenue: 59896000 Open source
2015-06-30	Operating margin	Not reported	Revenue: 85541000 Open source
2016-06-30	Operating margin	Not reported	Revenue: 60002000 Open source
2016-12-31	Operating margin	Not reported	Revenue: 48628000 Open source
2017-12-31	Operating margin	Not reported	Revenue: 115447000 Open source
2013-06-30	Net margin	Not reported	Revenue: 35535000 Open source
2014-06-30	Net margin	Not reported	Revenue: 59896000 Open source
2015-06-30	Net margin	Not reported	Revenue: 85541000 Open source
2016-06-30	Net margin	Not reported	Revenue: 60002000 Open source
2016-12-31	Net margin	Not reported	Revenue: 48628000 Open source
2017-12-31	Net margin	Not reported	Revenue: 115447000 Open source
20132013-06-30	Free cash flow margin	Not reported	Revenue: 35535000 Open source
20142014-06-30	Free cash flow margin	Not reported	Revenue: 59896000 Open source
20152015-06-30	Free cash flow margin	Not reported	Revenue: 85541000 Open source
20162016-06-30	Free cash flow margin	Not reported	Revenue: 60002000 Open source
20172016-12-31	Free cash flow margin	Not reported	Revenue: 48628000 Open source
20182017-12-31	Free cash flow margin	Not reported	Revenue: 115447000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

Not enough comparable data to show this history.

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(Unit12)	Source evidence
20132013-06-30	Operating cash flow	Not reported	No source recorded
20142014-06-30	Operating cash flow	Not reported	No source recorded
20152015-06-30	Operating cash flow	Not reported	No source recorded
20162016-06-30	Operating cash flow	Not reported	No source recorded
20172016-12-31	Operating cash flow	Not reported	No source recorded
20182017-12-31	Operating cash flow	Not reported	No source recorded

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

Not enough comparable data to show this history.

Values and sources

Free cash flow values and source evidence
Period	Series	Value	Source evidence
20132013-06-30	Free cash flow	Unavailable	No source recorded
20142014-06-30	Free cash flow	Unavailable	No source recorded
20152015-06-30	Free cash flow	Unavailable	No source recorded
20162016-06-30	Free cash flow	Unavailable	No source recorded
20172016-12-31	Free cash flow	Unavailable	No source recorded
20182017-12-31	Free cash flow	Unavailable	No source recorded

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2013-06-30	Liabilities / assets	Not reported	No source recorded
2014-06-30	Liabilities / assets	Not reported	No source recorded
2015-06-30	Liabilities / assets	Not reported	No source recorded
2016-06-30	Liabilities / assets	Not reported	No source recorded
2016-12-31	Liabilities / assets	Not reported	No source recorded
2017-12-31	Liabilities / assets	Not reported	No source recorded

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2013-06-30	Current assets / current liabilities	Not reported	No source recorded
2014-06-30	Current assets / current liabilities	Not reported	No source recorded
2015-06-30	Current assets / current liabilities	Not reported	No source recorded
2016-06-30	Current assets / current liabilities	Not reported	No source recorded
2016-12-31	Current assets / current liabilities	Not reported	No source recorded
2017-12-31	Current assets / current liabilities	Not reported	No source recorded

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2021 2020-01-01 – 2020-12-31	−Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 44.37 million Exact value Exact value: -44372000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 2020-01-01 – 2020-12-31: -44372000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA Inspect Net Income Open source Share or cite Citation for Net Income · ImmunoGen, Inc. · 2020-12-31 ImmunoGen, Inc. (edgar:855654) Net Income: -44372000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA Concept: fundies:NetIncome Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T03:05:41Z Snapshot: c9f8017d027214c342568b313855522615578f98fd10500a38e3fc0a88244ab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/855654/explain?concept=fundies%3ANetIncome&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA&dimensions= Input fundies:NetIncome: -44372000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/855654/000155837023002558/imgn-20221231x10k.htm#1152506 Filing: 000155837023002558 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 78.62 million Exact value Exact value: -78620000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 2020-01-01 – 2020-12-31: -78620000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ImmunoGen, Inc. · 2020-12-31 ImmunoGen, Inc. (edgar:855654) Operating Cash Flow: -78620000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA Concept: fundies:OperatingCashFlow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T03:05:41Z Snapshot: c9f8017d027214c342568b313855522615578f98fd10500a38e3fc0a88244ab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/855654/explain?concept=fundies%3AOperatingCashFlow&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA&dimensions= Input fundies:OperatingCashFlow: -78620000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/855654/000155837023002558/imgn-20221231x10k.htm#1358816 Filing: 000155837023002558 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 917,000 Exact value Exact value: 917000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 2020-01-01 – 2020-12-31: 917000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ImmunoGen, Inc. · 2020-12-31 ImmunoGen, Inc. (edgar:855654) Capital Expenditure: 917000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA Concept: fundies:CapitalExpenditure Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T03:05:41Z Snapshot: c9f8017d027214c342568b313855522615578f98fd10500a38e3fc0a88244ab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/855654/explain?concept=fundies%3ACapitalExpenditure&period=2020-12-31&surface=latest&period_type=duration&start=2020-01-01&unit=Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA&dimensions= Input fundies:CapitalExpenditure: 917000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/855654/000155837023002558/imgn-20221231x10k.htm#1367905 Filing: 000155837023002558 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 79.54 million Calculation and evidence -78620000 − 917000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA Exact free cash flow: -79537000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 2020-01-01 – 2020-12-31: -78620000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA · Inspect Operating Cash Flow · Source 2020-01-01 – 2020-12-31: 917000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ImmunoGen, Inc. · 2020-12-31 ImmunoGen, Inc. (edgar:855654) Free cash flow: -79537000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA Concept: free-cash-flow Period: 2020-01-01 to 2020-12-31 Values: Latest reported Published: 2026-11-02T03:05:41Z Snapshot: c9f8017d027214c342568b313855522615578f98fd10500a38e3fc0a88244ab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/855654?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -78620000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/855654/000155837023002558/imgn-20221231x10k.htm#1358816 Filing: 000155837023002558 Input fundies:CapitalExpenditure: 917000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA (2020-01-01 to 2020-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/855654/000155837023002558/imgn-20221231x10k.htm#1367905 Filing: 000155837023002558 The citation records this snapshot. The page link may show a newer release later.
2022 2021-01-01 – 2021-12-31	−Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 139.3 million Exact value Exact value: -139303000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 2021-01-01 – 2021-12-31: -139303000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA Inspect Net Income Open source Share or cite Citation for Net Income · ImmunoGen, Inc. · 2021-12-31 ImmunoGen, Inc. (edgar:855654) Net Income: -139303000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA Concept: fundies:NetIncome Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T03:05:41Z Snapshot: c9f8017d027214c342568b313855522615578f98fd10500a38e3fc0a88244ab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/855654/explain?concept=fundies%3ANetIncome&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA&dimensions= Input fundies:NetIncome: -139303000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/855654/000155837023002558/imgn-20221231x10k.htm#1190932 Filing: 000155837023002558 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 169.42 million Exact value Exact value: -169416000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 2021-01-01 – 2021-12-31: -169416000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ImmunoGen, Inc. · 2021-12-31 ImmunoGen, Inc. (edgar:855654) Operating Cash Flow: -169416000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA Concept: fundies:OperatingCashFlow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T03:05:41Z Snapshot: c9f8017d027214c342568b313855522615578f98fd10500a38e3fc0a88244ab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/855654/explain?concept=fundies%3AOperatingCashFlow&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA&dimensions= Input fundies:OperatingCashFlow: -169416000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/855654/000155837023002558/imgn-20221231x10k.htm#1357822 Filing: 000155837023002558 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 1.43 million Exact value Exact value: 1434000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 2021-01-01 – 2021-12-31: 1434000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ImmunoGen, Inc. · 2021-12-31 ImmunoGen, Inc. (edgar:855654) Capital Expenditure: 1434000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA Concept: fundies:CapitalExpenditure Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T03:05:41Z Snapshot: c9f8017d027214c342568b313855522615578f98fd10500a38e3fc0a88244ab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/855654/explain?concept=fundies%3ACapitalExpenditure&period=2021-12-31&surface=latest&period_type=duration&start=2021-01-01&unit=Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA&dimensions= Input fundies:CapitalExpenditure: 1434000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/855654/000155837023002558/imgn-20221231x10k.htm#1366824 Filing: 000155837023002558 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 170.85 million Calculation and evidence -169416000 − 1434000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA Exact free cash flow: -170850000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 2021-01-01 – 2021-12-31: -169416000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA · Inspect Operating Cash Flow · Source 2021-01-01 – 2021-12-31: 1434000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ImmunoGen, Inc. · 2021-12-31 ImmunoGen, Inc. (edgar:855654) Free cash flow: -170850000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA Concept: free-cash-flow Period: 2021-01-01 to 2021-12-31 Values: Latest reported Published: 2026-11-02T03:05:41Z Snapshot: c9f8017d027214c342568b313855522615578f98fd10500a38e3fc0a88244ab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/855654?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -169416000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/855654/000155837023002558/imgn-20221231x10k.htm#1357822 Filing: 000155837023002558 Input fundies:CapitalExpenditure: 1434000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA (2021-01-01 to 2021-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/855654/000155837023002558/imgn-20221231x10k.htm#1366824 Filing: 000155837023002558 The citation records this snapshot. The page link may show a newer release later.
2023 2022-01-01 – 2022-12-31	−Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 222.93 million Exact value Exact value: -222929000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 2022-01-01 – 2022-12-31: -222929000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA Inspect Net Income Open source Share or cite Citation for Net Income · ImmunoGen, Inc. · 2022-12-31 ImmunoGen, Inc. (edgar:855654) Net Income: -222929000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA Concept: fundies:NetIncome Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:05:41Z Snapshot: c9f8017d027214c342568b313855522615578f98fd10500a38e3fc0a88244ab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/855654/explain?concept=fundies%3ANetIncome&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA&dimensions= Input fundies:NetIncome: -222929000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/855654/000155837023002558/imgn-20221231x10k.htm#1237952 Filing: 000155837023002558 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 229.8 million Exact value Exact value: -229802000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 2022-01-01 – 2022-12-31: -229802000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · ImmunoGen, Inc. · 2022-12-31 ImmunoGen, Inc. (edgar:855654) Operating Cash Flow: -229802000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA Concept: fundies:OperatingCashFlow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:05:41Z Snapshot: c9f8017d027214c342568b313855522615578f98fd10500a38e3fc0a88244ab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/855654/explain?concept=fundies%3AOperatingCashFlow&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA&dimensions= Input fundies:OperatingCashFlow: -229802000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/855654/000155837023002558/imgn-20221231x10k.htm#1356810 Filing: 000155837023002558 The citation records this snapshot. The page link may show a newer release later.	Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 1.36 million Exact value Exact value: 1364000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 2022-01-01 – 2022-12-31: 1364000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · ImmunoGen, Inc. · 2022-12-31 ImmunoGen, Inc. (edgar:855654) Capital Expenditure: 1364000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA Concept: fundies:CapitalExpenditure Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:05:41Z Snapshot: c9f8017d027214c342568b313855522615578f98fd10500a38e3fc0a88244ab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/855654/explain?concept=fundies%3ACapitalExpenditure&period=2022-12-31&surface=latest&period_type=duration&start=2022-01-01&unit=Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA&dimensions= Input fundies:CapitalExpenditure: 1364000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/855654/000155837023002558/imgn-20221231x10k.htm#1365766 Filing: 000155837023002558 The citation records this snapshot. The page link may show a newer release later.	−Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 231.17 million Calculation and evidence -229802000 − 1364000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA Exact free cash flow: -231166000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA 2022-01-01 – 2022-12-31: -229802000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA · Inspect Operating Cash Flow · Source 2022-01-01 – 2022-12-31: 1364000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · ImmunoGen, Inc. · 2022-12-31 ImmunoGen, Inc. (edgar:855654) Free cash flow: -231166000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA Concept: free-cash-flow Period: 2022-01-01 to 2022-12-31 Values: Latest reported Published: 2026-11-02T03:05:41Z Snapshot: c9f8017d027214c342568b313855522615578f98fd10500a38e3fc0a88244ab0 Dimensions: Consolidated View: https://fundies.io/companies/edgar/855654?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -229802000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/855654/000155837023002558/imgn-20221231x10k.htm#1356810 Filing: 000155837023002558 Input fundies:CapitalExpenditure: 1364000 Unit_Standard_USD_tJIfDir9wE2PgWDp06uOZA (2022-01-01 to 2022-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/855654/000155837023002558/imgn-20221231x10k.htm#1365766 Filing: 000155837023002558 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

202 filings · 4,675 latest values · 4,669 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0000855654, 855654, IMGN, edgar:855654

Also known as IMMUNOGEN INC, ImmunoGen, Inc., ImmunoGen, Inc.

ImmunoGen, Inc.

Latest quarter

Revenue

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2018 2017-01-01 – 2017-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation